Suppr超能文献

内源性分泌的 GLP-1 不足以改变狗的餐后血糖调节。

Endogenously released GLP-1 is not sufficient to alter postprandial glucose regulation in the dog.

机构信息

Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

出版信息

Endocrine. 2011 Jun;39(3):229-34. doi: 10.1007/s12020-011-9441-x. Epub 2011 Mar 10.

Abstract

Glucagon-like peptide-1 (GLP-1) is secreted from the L cell of the gut in response to oral nutrient delivery. To determine if endogenously released GLP-1 contributes to the incretin effect and postprandial glucose regulation, conscious dogs (n = 8) underwent an acclimation period (t = -60 to -20 min), followed by a basal sampling period (t = -20 to 0 min) and an experimental period (t = 0-320 min). At the beginning of the experimental period, t = 0 min, a peripheral infusion of either saline or GLP-1 receptor (GLP-1R) antagonist, exendin (9-39) (Ex-9, 500 pmol/kg/min), was started. At t = 30 min, animals consumed a liquid mixed meal, spiked with acetaminophen. All animals were studied twice (± Ex-9) in random fashion, and the experiments were separated by a 1-2-week washout period. Antagonism of the GLP-1R did not have an effect, as indicated by repeated-measures MANOVA analysis of the Δ AUC from t = 45-320 min of arterial plasma glucose, GLP-1, insulin, glucagon, and acetaminophen levels. Therefore, endogenous GLP-1 is not sufficient to alter postprandial glucose regulation in the dog.

摘要

胰高血糖素样肽-1(GLP-1)是肠道 L 细胞响应口服营养物质输送而分泌的。为了确定内源性释放的 GLP-1 是否有助于肠促胰岛素效应和餐后血糖调节,清醒的狗(n = 8)经历了适应期(t = -60 至-20 分钟),随后是基础采样期(t = -20 至 0 分钟)和实验期(t = 0-320 分钟)。在实验期开始时,t = 0 分钟,开始外周输注生理盐水或 GLP-1 受体(GLP-1R)拮抗剂 Exendin(9-39)(Ex-9,500 pmol/kg/min)。在 t = 30 分钟时,动物摄入了含有对乙酰氨基酚的液体混合餐。所有动物均以随机方式两次(±Ex-9)进行研究,实验之间间隔 1-2 周的洗脱期。GLP-1R 拮抗作用没有影响,这表明重复测量 MANOVA 分析动脉血浆葡萄糖、GLP-1、胰岛素、胰高血糖素和对乙酰氨基酚水平的 t = 45-320 分钟的 Δ AUC 没有影响。因此,内源性 GLP-1 不足以改变狗的餐后血糖调节。

相似文献

1
Endogenously released GLP-1 is not sufficient to alter postprandial glucose regulation in the dog.
Endocrine. 2011 Jun;39(3):229-34. doi: 10.1007/s12020-011-9441-x. Epub 2011 Mar 10.
2
Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.
J Clin Endocrinol Metab. 2008 Dec;93(12):4909-16. doi: 10.1210/jc.2008-0605. Epub 2008 Sep 30.
4
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
J Clin Invest. 1998 Apr 1;101(7):1421-30. doi: 10.1172/JCI1349.
5
Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion.
Scand J Gastroenterol. 2011 Apr;46(4):428-35. doi: 10.3109/00365521.2010.537680. Epub 2010 Nov 30.
6
Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying.
J Clin Endocrinol Metab. 2011 Jan;96(1):229-36. doi: 10.1210/jc.2010-0841. Epub 2010 Nov 3.
8
Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.
Gastroenterology. 2014 Mar;146(3):669-680.e2. doi: 10.1053/j.gastro.2013.11.044. Epub 2013 Dec 4.
10
Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans.
Appetite. 2014 Nov;82:85-90. doi: 10.1016/j.appet.2014.07.009. Epub 2014 Jul 15.

本文引用的文献

1
Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog.
Am J Physiol Endocrinol Metab. 2013 Dec;305(12):E1473-82. doi: 10.1152/ajpendo.00354.2013. Epub 2013 Oct 22.
2
Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.
Diabetes. 2010 Jun;59(6):1330-7. doi: 10.2337/db09-1253. Epub 2010 Mar 9.
3
Exenatide can reduce glucose independent of islet hormones or gastric emptying.
Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E269-77. doi: 10.1152/ajpendo.90222.2008. Epub 2008 May 20.
4
Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization.
Am J Physiol Endocrinol Metab. 2008 Feb;294(2):E380-4. doi: 10.1152/ajpendo.00642.2007. Epub 2007 Dec 4.
5
Mechanisms of CCK signaling from gut to brain.
Curr Opin Pharmacol. 2007 Dec;7(6):570-4. doi: 10.1016/j.coph.2007.09.006. Epub 2007 Oct 22.
6
Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels.
Am J Physiol Endocrinol Metab. 2007 Oct;293(4):E1085-91. doi: 10.1152/ajpendo.00275.2007. Epub 2007 Aug 7.
7
Biology of incretins: GLP-1 and GIP.
Gastroenterology. 2007 May;132(6):2131-57. doi: 10.1053/j.gastro.2007.03.054.
8
Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action.
Am J Physiol Endocrinol Metab. 2006 Oct;291(4):E779-85. doi: 10.1152/ajpendo.00106.2005. Epub 2006 May 23.
10
Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs.
Am J Physiol Endocrinol Metab. 2003 May;284(5):E1027-36. doi: 10.1152/ajpendo.00503.2002. Epub 2003 Feb 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验